Background: Propofol is often used as an anesthetic agent for electroconvulsive therapy (ECT). In recent studies, propofol was shown to possess significant seizure-shortening properties during ECT. "Valproate" is a mood stabilizer used mainly in the treatment of bipolar affective disorder. It is reported that valproate, being an anticonvulsant, raises the seizure threshold, thus decreases the efficacy of ECT treatment.

Aim: The purpose of our study was to compare the dose of propofol in valproate-using patients and valproate-free patients.

Methods: In an open design, 17 patients with bipolar affective disorder manic episodes who were to be treated with valproate and ECT in combination, were compared with 16 manic-episode patients who were to be treated with ECT but not valproate. The two groups were compared on the basis of electroencephalography-registered seizure duration and the propofol dosage required to induce anesthesia.

Results: Valproate, compared with no valproate treatment, results in a decrease in the propofol dose required to induce anesthesia. In the valproate group of study participants, seizure duration was significantly shorter than in the valproate-free group.

Conclusion: The results suggest that valproate reduces the dose of propofol required for anesthesia during ECT treatment in patients with bipolar affective disorder manic episodes. Although propofol is a safe and efficacious anesthetic for ECT treatment, lower doses of propofol should be used to induce anesthesia for patients under valproate treatment. When the clinician needs to prolong seizure duration in patients treated with valproate, interruption of the valproate treatment or an anesthetic agent other than propofol should be considered.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949764PMC
http://dx.doi.org/10.2147/NDT.S59375DOI Listing

Publication Analysis

Top Keywords

bipolar affective
16
affective disorder
16
dose propofol
12
seizure duration
12
valproate treatment
12
propofol
10
valproate
10
electroconvulsive therapy
8
anesthetic agent
8
patients bipolar
8

Similar Publications

Mood variation under dual regulation of circadian clock and light.

Chronobiol Int

January 2025

Laboratory of Braintime, Graduate Institute of Mind, Brain and Consciousness (GIMBC), Taipei Medical University, Taipei, Taiwan.

The intricate relationship between circadian rhythms and mood is well-established. Disturbances in circadian rhythms and sleep often precede the development of mood disorders, such as major depressive disorder (MDD), bipolar disorder (BD), and seasonal affective disorder (SAD). Two primary factors, intrinsic circadian clocks and light, drive the natural fluctuations in mood throughout the day, mirroring the patterns of sleepiness and wakefulness.

View Article and Find Full Text PDF

Background: The basolateral complex of the amygdala is a crucial neurobiological site for Pavlovian conditioning. Investigations into volumetric alterations of the basolateral amygdala in individuals with major depressive disorder (MDD) have yielded conflicting results. These may be reconciled in an inverted U-shape allostatic growth trajectory.

View Article and Find Full Text PDF

Comprehensive bibliometric analysis of pharmacotherapy for bipolar disorders: Present trends and future directions.

World J Psychiatry

January 2025

The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, Jiangxi Province, China.

Background: Bipolar disorder (BD) is a severe mental illness characterized by significant mood swings. Effective drug treatment modalities are crucial for managing BD.

Aim: To analyze the current status and future trends of global research on BD drug treatment over the last decade.

View Article and Find Full Text PDF

Background: Options for 'treatment-resistant bipolar depression' (TRBD) are limited. Two small, short-term, trials of pramipexole suggest it might be an option.

Aims: To evaluate the clinical effectiveness and safety of pramipexole in the management of TRBD.

View Article and Find Full Text PDF

Purpose: Mood disorders frequently coexist with borderline personality pathology (BPP), presenting considerable clinical challenges. Affective temperaments (AT) play a role in modulating mood disorders and influence the manifestation of illness. BPP and AT share common characteristics, such as emotional instability, impulsivity, and difficulties in interpersonal relationships.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!